Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00125138 · ClinicalTrials.gov registry record · Phase 2
Melperone (an Anti-Psychotic) in Patients With Psychosis Associated With Parkinson's Disease
A Phase 2 study, sponsored by Lundbeck.
- Completed
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
NCT00125138: Completed Phase 2 study, sponsored by Lundbeck.
NCT00125138 is a Phase 2 study that has completed, run by Lundbeck. The registered enrollment target is 90 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (32% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00125138, a Phase 2 study, has completed, sponsored by Lundbeck.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of three target doses of melperone compared to placebo in the treatment of psychosis associated with Parkinson's disease. Subjects will be enrolled at approximately 20 investigational sites in the United States (U.S.) and 15 Ex-US sites. The maximum study duration will be 10 weeks. Subjects will have the option of continuing in an open-label extension study.
Primary Outcome
The change in the Scale for Assessment of Positive Symptoms (SAPS) total score. The SAPS total score ranges from 0 to 170, with higher scores indicating more severe psychosis.
Interventions
- DRUG Placebo
- DRUG Melperone HCl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2005-07 |
| Est. Completion | 2008-04 |
| Phase | Phase 2 |
What the finished NCT00125138 record still lists
NCT00125138 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (32% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00125138 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00125138 about?
NCT00125138 is a clinical study titled "Melperone (an Anti-Psychotic) in Patients With Psychosis Associated With Parkinson's Disease". The purpose of this study is to evaluate the safety and efficacy of three target doses of melperone compared to placebo in the treatment of psychosis associated with Parkinson's disease. Subjects will be enrolled at approximately 20 investigational sites in the United States (U.S.) and 15 Ex-US site...
What is the current status of trial NCT00125138?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2005-07. Estimated completion is 2008-04.
What interventions are being tested in trial NCT00125138?
The interventions under investigation include: Placebo (DRUG), Melperone HCl (DRUG).
Who is sponsoring clinical trial NCT00125138?
This trial is sponsored by Lundbeck, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00125138's enrollment target sits among peer trials
90 772nd of 2000 higher than 1,199 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia